52606-07-2

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-2,4-dimethoxypyridine is used as an intermediate in the synthesis of pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs.
Used in Agrochemical Production:
5-BroMo-2,4-diMethoxypyridine also serves as an intermediate in the production of agrochemicals, specifically in the creation of insecticides and herbicides. Its role in these applications is crucial for enhancing the effectiveness of these products.
Used in Drug Discovery and Development:
Due to its versatility and reactivity, 5-Bromo-2,4-dimethoxypyridine is a valuable asset in the field of drug discovery and development. It contributes to the advancement of new therapeutic agents and the improvement of existing ones.

Upstream product

• 26452-80-2 2,4-dichloropyridine 
• 18677-43-5 2,4-dimethoxypyridine 
• 17228-69-2 2-chloro-4-methoxy-pyridine 
• 1124-33-0 4-nitraminopyridine N-oxide 

Downstream Products

• 1033610-32-0 2,4-dimethoxy-5-(4-methoxyphenyIethynyl)pyridine 
• 1590410-99-3 C₁₂H₁₀FNO₂ 
• 1590403-59-0 C₁₉H₁₃F₄NO₃ 
• 1590403-60-3 C₁₈H₁₁F₄NO₃ 
• 1590403-61-4 C₁₈H₁₀ClF₄NO₂ 
• 1590403-62-5 C₁₈H₁₂F₄N₂O₂ 
• 1590403-63-6 C₂₅H₁₈F₄N₂O₂ 
• 1590403-78-3 C₂₀H₁₄F₄N₂O₃ 
• 1590411-00-9 C₂₆H₂₀F₄N₂O₃ 
• 1590403-80-7 C₂₁H₁₆F₄N₂O₃ 
• 1590403-79-4 C₂₂H₁₈F₄N₂O₄ 
• 1590403-65-8 C₂₅H₁₇F₄NO₃ 
• 1590403-66-9 C₂₄H₂₂F₄N₂O₄ 
• 1590403-76-1 C₂₄H₁₅F₄NO₃ 

Relevant academic research and scientific papers

AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES

The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive chromophore, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and ophthalmic devices. The present invention is also directed to a process of changing the optical properties of said ophthalmic device or a precursor article for manufacturing said ophthalmic device.

ANTI-FIBROTIC PYRIDINONES

This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses methods of preparing these polycyclic compounds, pharmaceutical compositions and medicaments comprising said compounds and methods to treat, prevent or diagnose diseases, disorders or conditions associated with fibrosis.

PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

ANTI-FIBROTIC PYRIDINONES

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

New bicyclic compounds as crac channel modulators

The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

CHEMICAL COMPOUNDS AND PROCESSES

The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which may possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.

NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS

The present invention relates to novel compounds, in particular novel pyridinone derivat ives according to Formula (I) X R1 N Y (I) R2 R3 wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subt ype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved. "